NOMOCAN PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTPHASE I - DEVELOPMENT OF THERAPEUTIC OR PRE

Nomocan Pharmaceuticals, Llc, Brooklyn NY

Investigators

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related deaths by 2030 with a 5-year overall survival rate is only about 13%. For the majority of PDAC patients with metastatic PC, the current standard of care is systemic chemotherapy, which only extends survival by a few months. There is a critical need for less toxic, more potent targeted therapeutics for PDAC. Details in Aims